Kura Oncology
KURA
98 hedge funds and large institutions have $442M invested in Kura Oncology in 2018 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 33 increasing their positions, 22 reducing their positions, and 8 closing their positions.
288% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 8
50% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 22
48% more capital invested
Capital invested by funds: $299M → $442M (+$143M)
29% more funds holding
Funds holding: 76 → 98 (+22)
6.03% more ownership
Funds ownership: 64.64% → 70.68% (+6%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
65% less call options, than puts
Call options by funds: $17K | Put options by funds: $49K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$45.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.55M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$6.42M |
| 4 |
SCM
Sio Capital Management
New York
|
+$5.17M |
| 5 |
Millennium Management
New York
|
+$4.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.03M |
| 2 |
Morgan Stanley
New York
|
-$3.47M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.65M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.53M |
| 5 |
NC
Nexthera Capital
New York
|
-$1.82M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SH
101
Sandia Holdings
Greenwich,
Connecticut
| – | -$922K | -60,240 | Closed |
|
|
PVI
102
Pura Vida Investments
New York
| – | -$765K | -50,000 | Closed |
|
|
DCM
103
Delpha Capital Management
New York
| – | -$23K | -1,479 | Closed |
|
|
PCM
104
Prelude Capital Management
New York
| – | -$14K | -900 | Closed |
|
105
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$9K | -600 | Closed |
|
106
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -94 | Closed |
|
KURA Hedge Fund Activity: Q1 2018 in Review
98 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2018, worth a combined $442M — up 48% from $299M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new KURA positions and 8 closed out — a net gain of 23 holders — while 33 added to existing stakes and 22 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $45.8M. The largest seller was PFM Health Sciences, cutting an estimated $8.03M.
- 98 institutional investors held Kura Oncology (KURA) as of Q1 2018, up from 76 in Q4 2017.
- Funds reported $442M of Kura Oncology stock for Q1 2018, up 48% quarter-over-quarter.
- 31 funds opened new Kura Oncology positions in Q1 2018 and 8 closed out, a net change of +23 holders.
- The largest Kura Oncology buyer in Q1 2018 was Fidelity Investments, an estimated $45.8M added.
- The largest Kura Oncology seller in Q1 2018 was PFM Health Sciences, an estimated $8.03M sold.
Based on aggregated 13F filings for Q1 2018.